WikiSWOT.com :: Free Merck SWOT Analysis

Pharmaceuticals & Biotech >> Merck SWOT Analysis:

Strengths

Global presence
Strong industry standing
Robust launch portfolio with revenue growth
underscored by the commercialization of
Januvia and Gardasil
High growth Zetia/Vytorin cardiovascular product franchise

Weaknesses

Patent expiry for biggest selling product franchise Zocor (mid 2006)
Weak core portfolio (comprising essentially Zetia/Vytorin) underscored by maturation and migration of key product franchises into expiry portfolio
Blockbuster growth strategy which closely ties Merck's position in certain therapy markets to just one or two products

Opportunities

Therapeutic diversification and expansion
into diabetes, oncology and infectious
diseases segments
Strong potential growth from vaccines
business, driven primarily (but not exclusively) by highly innovative, first-to-market cervical cancer vaccine Gardasil
Diversification into biologics market via
acquisitions of Abmaxis and GlycoFi

Threats

Continued exposure to patent expiries and risk of generic competition to key brands across forecast window 2006 to 2012; Fosamax in 2008, Cozaar/Hyzaar in 2009 and Singulair in 2012
In light of Merck's relatively weak core portfolio and its high generic-exposure expiry portfolio, the company is reliant on considerable sales growth from its launch portfolio, reflecting a higher risk growth strategy versus predominant core-driven growth

History: Version 14 (Newest), Version 13, Version 12, Version 11, Version 10, Version 9, Version 8, Version 7, Version 6, Version 5, Version 4, Version 3, Version 2, Version 1 (Oldest)

Go back to the SWOT analysis index, or start a discussion about Merck SWOT analysis by adding a comment below WikiSWOT Comments

Name
Email (not shared)
Website

Add comment